Clinical Trial Update: Safety and Efficacy Trial of a RNActive®-Derived Prostate Cancer Vaccine in Hormone Refractory Disease [Phase 1, Phase 2]

View source ↗

Summary

CureVac completed a Phase 1/2 trial assessing the safety and efficacy of an RNActive-derived prostate cancer vaccine in patients with hormone-refractory disease…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• RNActive-derived Prostate Cancer Vaccine

Snippet

Sponsor: CureVac | Conditions: Hormonal Refractory Prostate Cancer | Phase 1, Phase 2 | Status: COMPLETED